Takeda Pharmaceutical Co ADR (TAK) concluded trading on 01/11/24 at a closing price of $14.93, with 2.95 million shares of worth about $43.99 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -4.42% during that period and on Thursday the price saw a gain of about 0.34%. Currently the company’s common shares owned by public are about 3.14B shares, out of which, 3.14B shares are available for trading.
Takeda Pharmaceutical Co ADR (NYSE: TAK) started trading at $14.84, below -$0.04 from concluding price of the previous day. However, the stock later moved at a day high price of 14.95, or with a gain of 0.34%. Stock saw a price change of 2.61% in past 5 days and over the past one month there was a price change of 6.34%. Year-to-date (YTD), TAK shares are showing a performance of 4.63% which decreased to -3.05% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $13.19 but also hit the highest price of $17.15 during that period. The average intraday trading volume for Takeda Pharmaceutical Co ADR shares is 1.79 million. The stock is currently trading 5.03% above its 20-day simple moving average (SMA20), while that difference is up 6.51% for SMA50 and it goes to -2.73% lower than SMA200.
Takeda Pharmaceutical Co ADR (NYSE: TAK) currently have 3.14B outstanding shares and institutions hold larger chunk of about 2.55% of that.
The stock has a current market capitalization of $46.85B and its 3Y-monthly beta is at 0.58. PE ratio of stock for trailing 12 months is 33.73, while it has posted earnings per share of $0.44 in the same period. Its PEG reads 1686.62 and has Quick Ratio of 0.55 while making debt-to-equity ratio of 0.66. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TAK, volatility over the week remained 0.95% while standing at 1.01% over the month.
Analysts are in expectations that Takeda Pharmaceutical Co ADR (TAK) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -59.50% while it is estimated to increase by 66.97% in next year. EPS is likely to grow at an annualized rate of 0.02% for next 5-years, compared to annual growth of -6.94% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on March 16, 2023 offering a Buy rating for the stock and assigned a target price of $20 to it.
